Laboratorios Rovi : Q4 EBITDA and earnings beat on stronger CMO momentum
>Overall sales momentum softens less than expected on CMO and beats ours and consensus estimates - Total revenues decreased -3% y-o-y in Q4 2023 reaching € 235m, knocking our estimates and the consensus by +6% and +7% respectively yet posting a 13pp sequential deterioration (vs +10% in Q3, +2% in Q2 and -2% in Q1) due to a very tough comp on CMO (+60% in Q4 23). The beat is namely due to a less acute decline in the CMO unit (namely through the Moderna agreement). In t...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.